In 2021, the US Food and Drug Administration approved fosdenopterin, a cyclic pyranopterin monophosphate (cPMP) and precursor to molybdenum [7], as the first disease‐modifying treatment for MoCD type A caused by MOCS1 deficiency [8]. This evidence concerns the gene MOCS1 and hyperinsulinemic hypoglycemia, familial, 4.